News - NCS 8 mil grant

We’ve received an 8m grant from the Norwegian Cancer Society

The Norwegian Cancer Society has granted our lab NOK 7 970 000 for developing CRISPR-Cas gene therapy for blood cancer predisposition syndromes for 2022-2025.

The study proposes to develop CRISPR-based therapies for two rare childhood diseases (ADA2 deficiency and Nijmegen Breakage Syndrome) that make the patients susceptible to developing cancer.

In many of these types of cancer predisposition syndromes, the gene editing process can be problematic due to gene defects affecting DNA repair. 

Our study investigates this with the aim of developing alternative strategies to overcome risks of unexpected gene editing outcomes, with the hope that the results could also then be applied to other DNA repair diseases.

We are extremely happy that the Norwegian Cancer Society chose to fund our research into these rare childhood diseases. The research enabled by the grant will build further on the excellent preliminary data produced by our group members so far, and will allow us to hire more people into the group for another 3-4 years.

– Pavel Kopcil, Monika Szymanska, Ganna Reint and Jacob Conradi have all put in an enormous effort for setting up the mouse stem cell xenotransplant protocols that are necessary for conducting the proposed studies.

Latest news

We have a post-doc position currently open, focusing on single-cell sequencing of the CRISPR-corrected cells.
Kata went to American Society of Gene and Cell Therapy (ASGCT) conference in Baltimore, which focuses on novel translational findings in the field.
We had the pleasure of attending the 41st NSI Annual Meeting on November 24th, 2023!
We're excited to present our newest publication, published in the STAR Protocols journal in December 2023.
His lecture was titled “Kurativ behandling av monogenetiske sykdommer med genterapi. En ny tidsalder?” (Curative treatment of monogenetic diseases with gene therapy. A new age?).